113 related articles for article (PubMed ID: 9042256)
1. Partial synergism between dextran-conjugated doxorubicin and cancer drugs on the killing of multidrug resistant KB-V1 cells.
Fong WF; Lam W; Yang M; Wong JT
Anticancer Res; 1996; 16(6B):3773-8. PubMed ID: 9042256
[TBL] [Abstract][Full Text] [Related]
2. Synergism of energy starvation and dextran-conjugated doxorubicin in the killing of multidrug-resistant KB carcinoma cells.
Lam W; Chan H; Yang M; Cheng S; Fong W
Anticancer Drugs; 1999 Feb; 10(2):171-8. PubMed ID: 10211547
[TBL] [Abstract][Full Text] [Related]
3. Induction of multidrug resistance in MOLT-4 cells by anticancer agents is closely related to increased expression of functional P-glycoprotein and MDR1 mRNA.
Liu ZL; Onda K; Tanaka S; Toma T; Hirano T; Oka K
Cancer Chemother Pharmacol; 2002 May; 49(5):391-7. PubMed ID: 11976833
[TBL] [Abstract][Full Text] [Related]
4. Torilin, a sesquiterpene from Torilis japonica, reverses multidrug-resistance in cancer cells.
Kim SE; Kim YH; Kim YC; Lee JJ
Planta Med; 1998 May; 64(4):332-4. PubMed ID: 9619115
[TBL] [Abstract][Full Text] [Related]
5. Pervilleine A, a novel tropane alkaloid that reverses the multidrug-resistance phenotype.
Mi Q; Cui B; Silva GL; Lantvit D; Lim E; Chai H; You M; Hollingshead MG; Mayo JG; Kinghorn AD; Pezzuto JM
Cancer Res; 2001 May; 61(10):4030-7. PubMed ID: 11358822
[TBL] [Abstract][Full Text] [Related]
6. Cellular pharmacology of the partially non-cross-resistant anthracycline annamycin entrapped in liposomes in KB and KB-V1 cells.
Perez-Soler R; Ling YH; Zou Y; Priebe W
Cancer Chemother Pharmacol; 1994; 34(2):109-18. PubMed ID: 8194162
[TBL] [Abstract][Full Text] [Related]
7. Codelivery of Doxorubicin and Verapamil for Treating Multidrug Resistant Cancer Cells.
Williams JB; Buchanan CM; Pitt WG
Pharm Nanotechnol; 2018; 6(2):116-123. PubMed ID: 30207210
[TBL] [Abstract][Full Text] [Related]
8. Overexpression of P-glycoprotein in heat- and/or drug-resistant hepatoma variants.
Pirity M; Hevér-Szabó A; Venetianer A
Cytotechnology; 1996; 19(3):207-14. PubMed ID: 8862008
[TBL] [Abstract][Full Text] [Related]
9. The effect of fatty acids and analogues upon intracellular levels of doxorubicin in cells displaying P-glycoprotein mediated multidrug resistance.
Abulrob AN; Mason M; Bryce R; Gumbleton M
J Drug Target; 2000; 8(4):247-56. PubMed ID: 11144235
[TBL] [Abstract][Full Text] [Related]
10. Effects of cytochalasin congeners, microtubule-directed agents, and doxorubicin alone or in combination against human ovarian carcinoma cell lines in vitro.
Trendowski M; Christen TD; Acquafondata C; Fondy TP
BMC Cancer; 2015 Sep; 15():632. PubMed ID: 26357852
[TBL] [Abstract][Full Text] [Related]
11. β-Elemene, a compound derived from Rhizoma zedoariae, reverses multidrug resistance mediated by the ABCB1 transporter.
Guo HQ; Zhang GN; Wang YJ; Zhang YK; Sodani K; Talele TT; Ashby CR; Chen ZS
Oncol Rep; 2014 Feb; 31(2):858-66. PubMed ID: 24284783
[TBL] [Abstract][Full Text] [Related]
12. Reversal of cancer multidrug resistance by green tea polyphenols.
Mei Y; Qian F; Wei D; Liu J
J Pharm Pharmacol; 2004 Oct; 56(10):1307-14. PubMed ID: 15482646
[TBL] [Abstract][Full Text] [Related]
13. Toxicity and DNA binding of dextran-doxorubicin conjugates in multidrug-resistant KB-V1 cells: optimization of dextran size.
Lam W; Leung CH; Chan HL; Fong WF
Anticancer Drugs; 2000 Jun; 11(5):377-84. PubMed ID: 10912954
[TBL] [Abstract][Full Text] [Related]
14. Enhanced in vitro cytotoxicity of idarubicin compared to epirubicin and doxorubicin in rat prostate carcinoma cells.
Siegsmund MJ; Stendler A; Kreukler C; Köhrmann KU; Alken P
Eur Urol; 1997; 31(3):365-70. PubMed ID: 9129933
[TBL] [Abstract][Full Text] [Related]
15. Reversal of P-glycoprotein-mediated multidrug resistance by guggulsterone in doxorubicin-resistant human myelogenous leukemia (K562/DOX) cells.
Xu HB; Li L; Liu GQ
Pharmazie; 2009 Oct; 64(10):660-5. PubMed ID: 19947169
[TBL] [Abstract][Full Text] [Related]
16. Zosuquidar and an albumin-binding prodrug of zosuquidar reverse multidrug resistance in breast cancer cells of doxorubicin and an albumin-binding prodrug of doxorubicin.
Abu Ajaj K; Graeser R; Kratz F
Breast Cancer Res Treat; 2012 Jul; 134(1):117-29. PubMed ID: 22228402
[TBL] [Abstract][Full Text] [Related]
17. A novel doxorubicin-mitomycin C co-encapsulated nanoparticle formulation exhibits anti-cancer synergy in multidrug resistant human breast cancer cells.
Shuhendler AJ; Cheung RY; Manias J; Connor A; Rauth AM; Wu XY
Breast Cancer Res Treat; 2010 Jan; 119(2):255-69. PubMed ID: 19221875
[TBL] [Abstract][Full Text] [Related]
18. Expression of a full-length cDNA for the human "MDR1" gene confers resistance to colchicine, doxorubicin, and vinblastine.
Ueda K; Cardarelli C; Gottesman MM; Pastan I
Proc Natl Acad Sci U S A; 1987 May; 84(9):3004-8. PubMed ID: 3472246
[TBL] [Abstract][Full Text] [Related]
19. Levels of multidrug resistance (MDR1) P-glycoprotein expression by human breast cancer correlate with in vitro resistance to taxol and doxorubicin.
Mechetner E; Kyshtoobayeva A; Zonis S; Kim H; Stroup R; Garcia R; Parker RJ; Fruehauf JP
Clin Cancer Res; 1998 Feb; 4(2):389-98. PubMed ID: 9516927
[TBL] [Abstract][Full Text] [Related]
20. Effect of MDR1 phosphorothioate antisense oligodeoxynucleotides in multidrug-resistant human tumor cell lines and xenografts.
Ramachandran C; Wellham LL
Anticancer Res; 2003; 23(3B):2681-90. PubMed ID: 12894558
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
